Anzeige
Mehr »
Montag, 15.12.2025 - Börsentäglich über 12.000 News
Lithium wird plötzlich knapp: 3% Weltproduktion aktuell weg
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PX00 | ISIN: SE0013647385 | Ticker-Symbol: 49Z
Tradegate
15.12.25 | 17:13
1,689 Euro
-1,57 % -0,027
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
BICO GROUP AB Chart 1 Jahr
5-Tage-Chart
BICO GROUP AB 5-Tage-Chart
RealtimeGeldBriefZeit
1,6691,70717:30
1,6801,68817:30
PR Newswire
144 Leser
Artikel bewerten:
(0)

Leadgene Biosolutions, Inc., (Formerly CYTENA BPS), Announces Corporate Rebranding to Mark a New Phase of Growth within the Leadgene Group

TAIPEI, Dec. 15, 2025 /PRNewswire/ -- Leadgene Biosolutions, Inc. (formerly CYTENA BPS), following its transition out of the BICO Group, now officially integrates with Leadgene Biomedical, a biotechnology company specializing in recombinant proteins, antibodies, and diagnostic reagent development with integrated CRO/CDMO services. This alignment enables the combined organization to offer a full suite of bioprocessing products, solutions, and services across both research and industrial applications.

The integration provides Leadgene Biosolutions with a clear direction and expanded opportunities in global bioprocessing and cell-based research markets. The company will continue to advance its signature technologies, including the S.NEST, C.NEST, and C.BIRD microbioreactor systems - platforms recognized as the only solutions on the market capable of delivering true high-throughput 24- and 96-well culture with fully adjustable mixing, supported by integrated DO, pH, OCR, and ECAR monitoring. These technologies remain central to the organization's long-term vision, and future product families and expanded applications are being developed to support broader bioprocessing workflows and long-term metabolism assays.

"Building on proven strengths in bioprocessing, the integration gives Leadgene Biosolutions the expanded expertise to advance our long-term plans with refined focus." said Cheng-Han (Charles) Tsai, CEO of Leadgene Biosolutions. "The group now delivers one of the most complete end-to-end bioprocessing ecosystems, enabling customers to move faster from early research to clinical-ready workflows," added Dr. Chasel Yung-Chun Chuang, Chairman of Leadgene Biomedical.

All existing contracts, demo schedules, warranties, and support services remain fully intact. Gradual brand updates will introduce a more unified and forward looking identity that reflects the group's core vision.

Leadgene Biosolutions website: https://www.leadgene-biosolutions.com/

Leadgene Biomedical website: https://www.leadgenebio.com/

Cision View original content:https://www.prnewswire.co.uk/news-releases/leadgene-biosolutions-inc-formerly-cytena-bps-announces-corporate-rebranding-to-mark-a-new-phase-of-growth-within-the-leadgene-group-302642099.html

© 2025 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.